Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02337712 | Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer | unknown | Phase 2 | 198 | Sun Yat-sen UniversityOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03006575 | Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04706949 | Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment | unknown | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04636593 | A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | unknown | Phase 2 | 43 | First People's Hospital of HangzhouOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04696939 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | unknown | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04675008 | Central Nervous System(CNS) Efficacy of Dacomitinib | unknown | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04683198 | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | unknown | Phase 2 | 69 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 24, 2020 | clinicaltrials |
| NCT04684017 | Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 29 | Shanghai Chest HospitalOTHER | 1 | Dec 24, 2020 | clinicaltrials |
| NCT04675697 | Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer | unknown | Phase 2 | 36 | Xiangya Hospital of Central South UniversityOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | unknown | Phase 1 / Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04647357 | A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 30, 2020 | clinicaltrials |
| NCT04641754 | A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer | unknown | Phase 2 | 176 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04619537 | A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04619563 | A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04632342 | Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 87 | Hanlim Pharm. Co., Ltd.INDUSTRY | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02977169 | To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04369872 | Microwave Ablation of Primary and Secondary Lung Malignancies | unknown | Phase 1 / Phase 2 | 35 | University of CalgaryOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04620837 | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04612673 | A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC | unknown | Phase 2 | 33 | China Medical University, ChinaOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04102982 | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer(MWA in NSCLC) | unknown | Phase 2 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT04592666 | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer(APPEAL) | unknown | Phase 2 | 226 | Fudan UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03048500 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04553887 | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial(AUTUMN) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04560244 | A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04398940 | A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544644 | A Study of Combination Therapy in NSCLC | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 74 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 9, 2020 | clinicaltrials |
| NCT04520386 | OMT-111 for Terminal Stage Solid Tumors | unknown | Phase 2 | 78 | MetiMedi PharmaceuticalsINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04524299 | Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC | unknown | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04513301 | Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study | unknown | Phase 2 | 70 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04501029 | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer | unknown | Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03267654 | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2020 | clinicaltrials |
| NCT04486287 | Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 44 | Tianjin Medical University Second HospitalOTHER | 0 | Jul 24, 2020 | clinicaltrials |
| NCT03758677 | Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03420079 | A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation | unknown | Phase 1 / Phase 2 | 90 | Ahon Pharmaceutical Co., Ltd.OTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04470076 | Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation(Neoafa) | unknown | Phase 2 | 30 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Jul 14, 2020 | clinicaltrials |
| NCT03389087 | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03848611 | CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 20 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT03904719 | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | unknown | Phase 2 | 30 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT01746251 | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | unknown | Phase 2 | 92 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04459663 | JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. | unknown | Phase 2 | 50 | Li Zhang, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455594 | Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC(ANSWER) | unknown | Phase 2 | 168 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2021source: clinicaltrials